发展性药物用于沙尔科毒症
Ogugua Ndili Obi1, Lesley Ann Saketkoo2, Lisa A Maier3
1Division of Pulmonary Critical Care and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
Journal of autoimmunity
|March 28, 2024
概括
由于有限的已批准疗法和对类固醇节约选择的支持数据较弱,沙尔科病症治疗面临挑战. 本综述更新了 Sarcoidosis 的发育性药物和新途径,解决了试验设计的困难.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
背景情况:
- 肉病是一种多器官颗粒状疾病,原因不明.
- 超过一半的患者需要治疗,10-30%的患者患有慢性进展性疾病和肺纤维化.
- 目前的第一线疗法,普雷尼松,具有显著的毒性,而类固醇节约选择缺乏监管部门的批准和可靠的数据.
研究的目的:
- 为提供关于沙尔科毒性发育期药物的最新信息.
- 概述未来药物开发的新途径.
- 突出当前的临床试验,并讨论沙尔科毒症药物开发的挑战.
主要方法:
- 审查有关型硬化症治疗的当前文献.
- 对发育药物和新疗法途径的分析.
- 讨论罕见疾病临床试验设计中的挑战.
主要成果:
- 对于严重的,耐火性沙尔科毒症,存在有限的批准治疗选择.
- 需要扩大治疗策略和进行良好临床试验.
- 目前正在探索新的 Sarcoidosis 治疗途径.
结论:
- 由于目前治疗方法的选择有限和毒性严重,开发新型的沙尔科毒症治疗方法至关重要.
- 应对临床试验设计的挑战,包括患者异质性和结果测量,对于推进沙丘病研究至关重要.
- 未来的研究应该专注于针对新型治疗点和现有药物的精心设计的试验.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
291
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
291
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs Used in Lower Respiratory Disorders: Overview
437
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
437
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
243
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
243
Drug Delivery: Miscellaneous Routes
338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338


